Drugs that inhibit cancer-causing proteins known as kinases have driven nearly $100 billion in deals since 2010, SVB Leerink finds.…More

A group of investors sued Novo Nordisk in Denmark for allegedly misleading the public about its insulin franchise’s downward spiral.…More

Valeant changed its name to Bausch Healthcare last year to distance itself from controversy, but one of the company’s old…More

Roche’s targeted cancer drug Rozlytrek officially has its U.S. green light—and in not just one, but two cancer types. Thursday,…More

Debt-rating firm Moody’s revised its Teva outlook from “stable” to “negative” as the company deals with challenges ranging from opioid…More

Congressional watchdogs Rep. Elijah Cummings and Sen. Bernie Sanders have tried and failed to get drug pricing info from Mylan,…More

The way Teva CEO Kåre Schultz figures it, manufacturing is the cost-cutting gift that keeps on giving. After the company…More